**DERMSCAN ASIA Co., Ltd.**
3300/46-47 29th. Floor, Tower A
Elephant Tower, Phaholyothin Road,
Chomphon, Chatujak
Bangkok 10900
THAILAND

Tel. + 66 2 937 4377
www.dermscanasia.com

**CHEERTSUME CO., LTD.**

24/6 Moo 4, Bang Khanun,
Bang Kruai, Nonthaburi 11130
THAILAND

Bangkok, January 16, 2026

**Study Report# DA25A635 (version 1.0)**
Related to quote# DA25A635

# EVALUATION OF THE ACUTE CUTANEOUS TOLERANCE OF A COSMETIC PRODUCT ON ADULT SUBJECTS SINGLE PATCH TEST

**CMe CheerTsuMe - Ultra - Light Refreshing Facial Sunscreen SPF50+ PA++++**
**(Batch number : 20/11/25) (Formula reference : UV0431.13)**

**CLINICAL INVESTIGATION CENTER:**
**Dermscan Project Manager**
**Pimrumpa VICHITNARK: pvi@dermscanasia.com**
**Project Manager Assistant**
**Parisa SRIWONG: psr@dermscanasia.com**

**Investigator: Dermatologist**
**Dr. Sujittra SOMBUNTHAM**

*Dermscan Asia is certified ISO 9001 : 2015*

including 15 pages

## TABLE OF CONTENTS

## SUMMARY OF THE STUDY REPORT# DA25A635

### EVALUATION OF THE ACUTE CUTANEOUS TOLERANCE OF A COSMETIC PRODUCT ON ADULT SUBJECTS: SINGLE PATCH TEST

**Objective**

To determine the acute irritating potential of a cosmetic product after single application under patch-test.

**Methodology**

Descriptive, Monocentric and single blind study.

**Kinetics**

| | D0 | D2 | D2 t30min | D3 t24h |
|---|---|---|---|---|
| Collection of the subject's informed consent | ● | | | |
| Verification of inclusion and non-inclusion criteria | ● | | | |
| Patch-test : application | ● | | | |
| Patch-test : removal | | ● | | |
| Clinical scoring | | | ● | ● |

**Dates**

| Product reception: | Study start: | Study end: |
|---|---|---|
| November 27, 2025 | December 15, 2025 | December 18, 2025 |

**Product**

| Reference: | Form: | Storage temperature: |
|---|---|---|
| CMe CheerTsuMe - Ultra - Light Refreshing Facial Sunscreen SPF50+ PA++++ (Batch number : 20/11/25) (Formula reference : UV0431.13) | Opaque yellowish cream | Room temperature *(Thailand climate)* |

**Application**

| Zone: | Patch duration: | Concentration | Patch type: |
|---|---|---|---|
| Scapular part of the back | 48 hours | Pure | Occlusive |

**Studied Population**

| Main inclusion criteria | Average age: | Number of subjects analysed: |
|---|---|---|
| Age ≥ 18 years old.<br>Phototype I to IV. | 49±2 years<br>(29 – 60) | 22 |

**Results**

**M.C.I.I. value : 0.07**

**Conclusion: Non irritating**

**Investigator: Dermatologist**

| Name and quality: | Date: | Signature: |
|---|---|---|
| **Sujittra SOMBUNTHAM** | **January 26, 2026** | Sujittra Sombunthan Digitally signed by Sujittra SOMBUNTHAM DN: cn=Sujittra SOMBUNTHAM, o, ou, email=technical@dermscanasia.com, c=TH Date: 2026.01.26 13:35:31 +07'00' |

# 1. EXPERIMENTAL PROTOCOL

The study was conducted according to the current internal procedures.

## 1.1. Subjects

### 1.1.1. Characteristics of included subjects

- 22 subjects with every skin type were included in the study:

| | |
|---|---|
| Female subjects | 18 |
| Male subjects | 4 |
| Age (mean±SEM) | 29 to 60 years old (49±2) |

### 1.1.2. Inclusion criteria

- subjects having given their informed, written consent,
- no previous experience of intolerance or allergic reactions to this kind of product,
- phototype I to IV.

### 1.1.3. Non-inclusion criteria

- pregnant or breast-feeding women or women planning to be pregnant during the study,
- cutaneous pathology on the study zone (psoriasis, eczema, vitiligo, pityriasis versicolor, acne, etc…),
- subjects with medical treatments which may interfere with the acute skin tolerance evaluation, according to the investigator,
- exposure to the sun or to UV rays on the back during the previous month,
- subjects with very irritative skin,
- subjects presenting an important hairiness of the back, freckles, beauty spots or a tattoo on the back,
- subjects with a serious or progressive disease,
- excessive use of alcohol or tobacco.

## 1.2. Study product

The product supplied by the sponsor had the following specifications:

| Product reference | Product aspect | Receipt date at Dermscan Asia |
|---|---|---|
| CMe CheerTsuMe - Ultra - Light Refreshing Facial Sunscreen SPF50+ PA++++ (Batch number : 20/11/25) (Formula reference : UV0431.13) | Opaque yellowish cream | November 27, 2025 |

## 1.3. Methodology

### 1.3.1. Instruments, dose, duration

The studied product was applied under the following conditions:

| | |
|---|---|
| Areas: | Scapular part of the back |
| Patch tests type: | Finn Chamber® 8mm (50mm²) – occlusive |
| Dose* : | 25 µl |
| Application conditions: | Pure |
| Application duration: | 48 hours |
| Control: | Patch without product |

*Note: The quantity is determined according to the cupule capacity, indicated by the manufacturer

### 1.3.2. Readings

The macroscopic skin examinations were carried out under the same conditions, specifically the lighting (standardized light), 30 minutes after removal of the patch tests and 24 hours later. If the subject had a cutaneous reaction >1, he had to return to the centre and readings were done until complete reversibility of the cutaneous reactions.

The grading of the possible irritation reaction, on each zone that received the studied product and on the control zone, was done according to the following scale:

| Score | Quotation | **CRITERIA**: | |
|---|---|---|---|
| | | ERYTHEMA «**E**» | OEDEMA «**O**» |
| 0 | Absent | no erythema | no oedema |
| 0.5 | Very slight | fairly detectable: discreet pinkness of one part of the tested area | palpable, barely visible |
| 1 | Slight | discreet pinkness of the complete tested area or rather visible on one part of the tested area | palpable, visible |
| 2 | Obvious | clearly distinguishable, dull red erythema covering the whole tested area | obvious oedema (thickness < 1 mm) with or without papule(s) or vesicle(s) |
| 3 | Important | deep dark or fiery bright red color covering all the tested area or moderate erythema diffusing outside the tested area | severe oedema (thickness ≥ 1 mm or diffusing outside the tested area) with or without vesicle(s) or blister(s) |

A change in skin structure (dryness (D), roughness (R), thickness (T), reflectivity (Re)) that could be linked to the nature of the studied product or one of its components is clinically described and its intensity graded according to the following scale:

0.5 = doubtful
1 = slight
2 = obvious
3 = important.

### 1.3.3. Result interpretation

The analysis and the interpretation were carried out according to the results obtained in the experimental conditions. They are descriptive and completed by the calculation of the cumulative irritation index (C.I.I.) for each subject according to the formula:

$$C.I.I. = \frac{\sum \text{of the grade (erythema + oedema)}}{\text{Number of readings}}$$

This index is then divided by the number of subjects in order to obtain the Mean Cumulative Irritation Index (M.C.I.I.):

$$M.C.I.I. = \sum C.I.I. / \text{number of subjects}$$

The obtained index (maximum 6) allow to arbitrarily classify the studied product according to the following scale:

| M.C.I.I. | Class |
|---|---|
| M.C.I.I. < 0.25 | Non irritating (NI) |
| 0.25 ≤ M.C.I.I. < 0.50 | Very slightly irritating (VSI) |
| 0.5 ≤ M.C.I.I. < 1 | Slightly irritating (SI) |
| 1 ≤ M.C.I.I. < 2 | Moderately irritating (MI) |
| M.C.I.I. ≥ 2 | Irritating (I) |

Individual values and the product class were taken into account to write a suitable conclusion under the study conditions.

### 1.3.4. Bibliography:

1. COLIPA "Cosmetic product test guidelines for the assessment of human skin compatibility" 2nd edition – August 1997.

2. Patch-testing with the patient's own products - Peter J. FROSCH, Johannes GEIER, Wolfgang UTER, An GOOSENS - CONTACT DERMATITIS 4TH EDITION – 2006

3. Comparison of the cumulative irritation potential of Adapalene gel and cream with that of Erythromycin/Tretinoin solution and gel and Erythromycin/Tretinoin gel - Catherine QUEILLE-ROUSSEL, Michel PONCET, Stephane MESAROS, Alan CLUCAS, Michael BAKER and Andrew-Marc SOLOFF - CLINICAL THERAPEUTICS / VOL.23 N°2, 2001

## 2. RESULTS-CONCLUSION

The individual reading results at each experimental time are presented in the APPENDIX I.

The readings at 30 minutes and 24 hours after patch-tests removal gave of the following M.C.I.I value:

| Product reference | Conditions | Patch duration | M.C.I.I. | Conclusion |
|---|---|---|---|---|
| **CMe CheerTsuMe - Ultra - Light Refreshing Facial Sunscreen SPF50+ PA++++ (Batch number : 20/11/25) (Formula reference : UV0431.13)** | - **Concentration : Pure**<br>- **Patch tests type: Occlusive** | **48 hours** | **0.07** | **Non irritating** |

## 3. ETHICAL CONSIDERATION

The study had to be risks were determined to be minimal for the safety of the test subjects.

So, according to the procedure of the investigating centre, the protocol, the information sheet and informed consent and the information concerning the investigational product (particularly referring to its safety) had to be submitted to the opinion of an Institutional Ethics Committee.

The Institutional Ethics Committee gave the approval on expedited approval certificate no. EXPA#4043

The study began after the approval of the Institutional Ethics Committee.

### 3.1. CONFIDENTIALITY AND GENERAL DATA PROTECTION REGULATION

In this study, Dermscan Asia processes personal data of subjects on behalf of the Sponsor, in accordance with the rules on the protection of personal data and in particular, Thailand's Personal Data Protection Act B.E. 2562 (2019) ("PDPA") comes into full force on 1 June 2022, on the protection of natural persons regarding the processing of personal data.
A key element of the PDPA are the rights protecting data subjects, such as Section 19 which grants data subjects the right to withdraw consent at any time, Section 32 the right to object to collection, use or disclosure of personal data and Section 73 the right to file a complaint in case of violation, among others.

For this purpose, Dermscan Asia limits the collection and use of personal data to that which is needed for analysis and control purposes, by ensuring their security and integrity and by guaranteeing their confidentiality.
Dermscan Asia makes sure beforehand and throughout the duration of the data-processing:
of the compliance with the obligations of the applicable data protection law,
to inform subjects of their personal data-processing after obtaining their consent,
to implement and maintain appropriate technical and organizational measures.

An identification code is attributed to each subject for the purpose to keep his/her identity confidential. This code consists of the first two letters/first letter of the subject's name and the first letter of his/her first name.
The concerned subject must be informed of the identity and the contact details of the Controller and, where applicable, of the controller's representative. However, considering the objective of the study, to avoid any bias in the investigational product evaluation, the identity of the Sponsor is not revealed to the subject participating.

**APPENDIX I**

**SUBJECTS CHARACTERISTICS**

**TABLES OF THE READINGS**

**FORMULA**

## SUBJECTS CHARACTERISTICS

| Subject# | Last name | First name | Age | Sex | Phototype | Inclusion date | End date |
|---|---|---|---|---|---|---|---|
| 1 | SO | A | 43 | F | IV | December 15, 2025 | December 18, 2025 |
| 2 | LA | P | 39 | F | IV | December 15, 2025 | December 18, 2025 |
| 3 | CH | S | 59 | M | IV | December 15, 2025 | December 18, 2025 |
| 4 | KA | H | 50 | F | IV | December 15, 2025 | December 18, 2025 |
| 5 | SR | R | 52 | F | IV | December 15, 2025 | December 18, 2025 |
| 6 | SR | B | 59 | F | IV | December 15, 2025 | December 18, 2025 |
| 7 | TA | P | 54 | F | IV | December 15, 2025 | December 18, 2025 |
| 8 | PA | H | 55 | M | IV | December 15, 2025 | December 18, 2025 |
| 9 | PH | S | 50 | F | III | December 15, 2025 | December 18, 2025 |
| 10 | SR | S | 57 | F | IV | December 15, 2025 | December 18, 2025 |
| 11 | PI | M | 38 | F | IV | December 15, 2025 | December 18, 2025 |
| 12 | BO | P | 53 | F | IV | December 15, 2025 | December 18, 2025 |
| 13 | AR | W | 48 | F | IV | December 15, 2025 | December 18, 2025 |
| 14 | PA | P | 29 | F | IV | December 15, 2025 | December 18, 2025 |
| 15 | AN | C | 55 | M | IV | December 15, 2025 | December 18, 2025 |
| 16 | SU | P | 45 | F | III | December 15, 2025 | December 18, 2025 |
| 17 | SU | S | 45 | F | III | December 15, 2025 | December 18, 2025 |
| 18 | CH | C | 60 | F | III | December 15, 2025 | December 18, 2025 |
| 19 | CH | J | 47 | F | III | December 15, 2025 | December 18, 2025 |
| 20 | RU | S | 48 | M | IV | December 15, 2025 | December 18, 2025 |
| 21 | PH | S | 53 | F | IV | December 15, 2025 | December 18, 2025 |
| 22 | RU | P | 45 | F | III | December 15, 2025 | December 18, 2025 |

| | | | | | |
|---|---|---|---|---|---|
| **Mean** | **49** | **F** | 18 | **I** | 0 |
| Minimum | 29 | **M** | 4 | **II** | 0 |
| Maximum | 60 | | | **III** | 6 |
| **SEM** | **2** | | | **IV** | 16 |
| 95% CI | 3 | | | | |

F = Female

M = Male

()*: values not included in the analysis

**TABLE OF READINGS**

| Subject | Reading in 30 minutes after patch removal | | | | | Reading in 24 hours after patch removal | | | | | C.I.I. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| | Control | | Product | | Change in skin structure | Control | | Product | | Change in skin structure | |
| | E | O | E | O | | E | O | E | O | | |
| 1 | 0 | 0 | 0 | 0 | no change | 0 | 0 | 0 | 0 | no change | 0.00 |
| 2 | 0 | 0 | 0 | 0 | no change | 0 | 0 | 0 | 0 | no change | 0.00 |
| 3 | 0 | 0 | 0.5 | 0 | no change | 0 | 0 | 0.5 | 0 | no change | 0.50 |
| 4 | 0 | 0 | 0.5 | 0 | no change | 0 | 0 | 0 | 0 | no change | 0.25 |
| 5 | 0 | 0 | 0 | 0 | no change | 0 | 0 | 0 | 0 | no change | 0.00 |
| 6 | 0 | 0 | 0 | 0 | no change | 0 | 0 | 0 | 0 | no change | 0.00 |
| 7 | 0 | 0 | 0 | 0 | no change | 0 | 0 | 0 | 0 | no change | 0.00 |
| 8 | 0 | 0 | 0 | 0 | no change | 0 | 0 | 0 | 0 | no change | 0.00 |
| 9 | 0 | 0 | 0 | 0 | no change | 0 | 0 | 0 | 0 | no change | 0.00 |
| 10 | 0 | 0 | 0 | 0 | no change | 0 | 0 | 0 | 0 | no change | 0.00 |
| 11 | 0 | 0 | 0.5 | 0 | no change | 0 | 0 | 0.5 | 0 | no change | 0.50 |
| 12 | 0 | 0 | 0 | 0 | no change | 0 | 0 | 0 | 0 | no change | 0.00 |
| 13 | 0 | 0 | 0 | 0 | no change | 0 | 0 | 0 | 0 | no change | 0.00 |
| 14 | 0 | 0 | 0 | 0 | no change | 0 | 0 | 0 | 0 | no change | 0.00 |
| 15 | 0 | 0 | 0 | 0 | no change | 0 | 0 | 0 | 0 | no change | 0.00 |
| 16 | 0 | 0 | 0 | 0 | no change | 0 | 0 | 0 | 0 | no change | 0.00 |
| 17 | 0 | 0 | 0 | 0 | no change | 0 | 0 | 0 | 0 | no change | 0.00 |
| 18 | 0 | 0 | 0 | 0 | no change | 0 | 0 | 0 | 0 | no change | 0.00 |
| 19 | 0 | 0 | 0 | 0 | no change | 0 | 0 | 0 | 0 | no change | 0.00 |
| 20 | 0 | 0 | 0 | 0 | no change | 0 | 0 | 0 | 0 | no change | 0.00 |
| 21 | 0 | 0 | 0.5 | 0 | no change | 0 | 0 | 0 | 0 | no change | 0.25 |
| 22 | 0 | 0 | 0 | 0 | no change | 0 | 0 | 0 | 0 | no change | 0.00 |
| | | | | | | | | | | M.C.I.I. | 0.07 |

Product = "CMe CheerTsuMe - Ultra - Light Refreshing Facial Sunscreen SPF50+ PA++++ (Batch number : 20/11/25) (Formula reference : UV0431.13)"
E = Erythema
O = Oedema
()*: values not included in data analysis

# FORMULA

PARTIE VIII – FORMULE / *FORMULA*

Formule quantitative à fournir avant le début de(s) l'évaluation(s) :

MERCI DE NOUS COMPLETER LE TABLEAU SUIVANT

**En précisant bien chaque information demandée (Noms chimiques + INCI + n° CAS + fonctions prévues des ingrédients) et en donnant le pourcentage exacte de chaque ingrédient pour un rapport total à 100% (ne pas noter de QSP)**

*Quantitative formula to supply before the beginning of the evaluation(s):*

*THANKS TO FILL THE FOLLOWING TABLE*

***Please specify each requested information (Chemical names + INCI + CAS# + functions of each ingredient reported to 100%)***

type de produit : / *type of product:*

reference :

**Merci de ne saisir qu'un ingrédient par ligne / *Please enter only one ingredient by line***

| NUMERO CAS / *CAS NUMBER* | NOM INCI / *INCI NAME* | CONCENTRATION / *CONCENTRATION* | FONCTION / *FUNCTION* | NOM CHIMIQUE / *CHEMICAL NAME* | n° EINECS/ELINCS (Ec No.) / *n° EINECS/ELINCS (Ec No.)* | NOM COMMERCIAL / *TRADE NAME* |
|---|---|---|---|---|---|---|
| 7732-18-5 | Aqua | 36.36 | SOLVENT | | 231-791-2 | DIW |
| 139-33-3 | Disodium EDTA | 0.1 | CHELATING | | 205-358-3 | 2NA-ED |
| 56-81-5 | Glycerine | 0.4985 | HUMECTANT | | 200-289-5 | GL |
| 7732-18-5 | aqua | 0.0015 | SOLVENT | | 231-791-2 | GL |
| | Ammonium Acryloyldimethyltaurate/VP Copolymer | 0.25 | VISCOSITY CONTROLLING | | | AVC |
| 111286-86-3 | Hydroxyethyl Acrylate/Sodium Acryloyldimethyl Taurate Copolymer | 0.2125 | VISCOSITY CONTROLLING | | | SEPI-10 |
| | Polysorbate | 0.01375 | SURFACTANT - EMULSIFYING | | | SEPI-10 |
| 71902-01-7 | Sorbitan isostearate | 0.01375 | SURFACTANT - EMULSIFYING | | 276-171-2 | SEPI-10 |
| 7732-18-5 | Water | 0.01 | SOLVENT | | 231-791-2 | SEPI-10 |
| 7732-18-5 | Aqua | 1 | SOLVENT | | 231-791-2 | DIW |
| 13463-67-7 | Titanium dioxide | 0.08 | COLORANT | | 236-675-5 | EURO TI |
| 12694-22-3 | Polyglyceryl-2 Stearate | 0.675 | SURFACTANT - EMULSIFYING | | 235-777-7 | Poly 2w |
| 31566-31-1 | Glyceryl Stearate | 0.45 | SURFACTANT - EMULSIFYING | | 250-705-4/286-490-9 | Poly 2w |
| 112-92-5 | Stearyl Alcohol | 0.375 | VISCOSITY CONTROLLING | | 204-017-6 | Poly 2w |
| 19035-79 -1 | Potassium Cetyl Phosphate | 1.5 | SURFACTANT - EMULSIFYING | | 242-768-1 | Romol AFSK |
| | Polyglyceryl-3 methylglucose distearate | 0.5 | SURFACTANT - EMULSIFYING | | | TEGO CARE 450 |
| 36653-82-4 | Cetyl Alcohol | 0.525 | VISCOSITY CONTROLLING | | 253-149-0 | EMUL DEL |
| 31566-31-1 | Glyceryl Stearate | 0.525 | SURFACTANT - EMULSIFYING | | 250-705-4 | EMUL DEL |
| 9004-99-3 | PEG-75 Stearate | 0.15 | SURFACTANT - CLEANSING | | | EMUL DEL |
| 9004-95-9 | Ceteth-20 | 0.15 | SURFACTANT - EMULSIFYING | | | EMUL DEL |
| 9005-00-9 | Steareth-20 | 0.15 | SURFACTANT - EMULSIFYING | | | EMUL DEL |
| | Dibutyl Adipate | 5 | SKIN CONDITIONING - EMOLLIENT | | | Cetiol B |
| | Diethylamino Hydroxybenzoyl Hexyl Benzoate | 7 | UV FILTER | | | Uvinul A+ |
| | Ethylhexyl Triazone | 3 | UV FILTER | | | Parsol EHT |
| 118-60-5 | Ethylhexyl salicylate | 4 | UV FILTER | | 204-263-4 | Parsol EHS |
| 70356-09-1 | Butyl Methoxydibenzoylmethane | 3 | UV FILTER | | 274-581-6 | EULEX 9020 |
| 59219-71-5 | ISONONYL ISONONANOATE | 5 | SKIN CONDITIONING - EMOLLIENT | | 261-665-2 | KAK 99 |
| 629-82-3 | DICAPRYLYL ETHER | 5 | SKIN CONDITIONING - EMOLLIENT | | 211-112-6 | CET OE |
| 68411-27-8 | C12-15 alkyl benzoate | 4 | SKIN CONDITIONING - EMOLLIENT | | 270-112-4 | DUB B 1215 |
| 68131-39-5 | C12-15 Pareth-12 | 3.5 | SKIN CONDITIONING - EMOLLIENT | | | MULSIFAN RT 203/80 |
| 9003-04-7 | Sodium Polyacrylate | 0.18 | VISCOSITY CONTROLLING | | | AQG 45 |
| 64742-47-8 | C13-14 Isoparaffin | 0.1 | SKIN CONDITIONING - EMOLLIENT | | | AQG 45 |
| 3055-97-8 | Laureth-7 | 0.016 | SKIN CONDITIONING - EMOLLIENT | | 221-283-9 | AQG 45 |
| 7732-18-5 | Water | 0.104 | SOLVENT | | 231-791-2 | AQG 45 |
| 7732-18-5 | Aqua | 4 | SOLVENT | | 231-791-2 | DIW |
| | Methylene Bis-Benzotriazolyl Tetramethylbutylphenol (nano) | 3 | UV FILTER | | | Tinosorb M |
| 68515-73-1 | Decyl Glucoside | 0.48 | EMULSION STABILISING | | 259-218-1 | Tinosorb M |
| 57-55-6 | Propylene Glycol | 0.024 | SKIN CONDITIONING - EMOLLIENT | | 200-338-0 | Tinosorb M |
| | Xanthan Gum | 0.018 | VISCOSITY CONTROLLING | | | Tinosorb M |
| | Aqua / Water | 2.478 | SOLVENT | | 231-791-2 | Tinosorb M |
| 84696-19-5 | Hamamelis virginiana leaf water | 0.0994 | ACTIVE | | 283-637-9 | Witch Hazel ORG |
| 24634-61-5 | Potassium sorbate | 0.0002 | PRESERVATIVE | | 246-376-1 | Witch Hazel ORG |
| 532-32-1 | Sodium benzoate | 0.0002 | PRESERVATIVE | | 208-534-8 | Witch Hazel ORG |
| 77-92-9 / 5949-29-1 | Citric acid | 0.0002 | BUFFERING | | 201-069-1 | Witch Hazel ORG |
| 85507-69-3 / 94349-62-9 | Aloe Barbadensis Leaf Extract | 0.0994 | ACTIVE | | 287-390-8 / 305-181-2 | Aloe W ORG |
| 77-92-9 / 5949-29-1 | Citric acid | 0.0003 | BUFFERING | | 201-069-1 | Aloe W ORG |
| 532-32-1 | Sodium Benzoate | 0.0003 | PRESERVATIVE | | 208-534-8 | Aloe W ORG |
| 7695-91-2 | DL-ALPHA-TOCOPHERYL ACETATE | 0.01 | ANTIOXIDANT | | 231-710-0 | VE ACET |
| 57-55-6 | Propylene Glycol | 0.079 | HUMECTANT | | 200-338-0 | Actiphyte oat meal ph |
| 7732-18-5 | Water | 0.079 | SOLVENT | | 231-791-2 | Actiphyte oat meal ph |
| | Avena Sativa (Oat) Meal Extract | 0.04 | ACTIVE | | | Actiphyte oat meal ph |
| | Phenoxyethanol | 0.002 | PRESERVATIVE | | | Actiphyte oat meal ph |
| | zinc chlopide | 0.1 | ANTIMICROBIAL | | | Zinc Sebum |
| 225234-03-7 / 90106-68-6 | Hippophae Rhamnoides Oil | 0.05 | SKIN CONDITIONING - EMOLLIENT | | - / 290-292-8 | sea buckton |
| | PEG-15/PPG-70 Glyceryl Ether/IPDI/DMPA Crosspolymer | 2 | ANTICAKING | | | Beau S |
| 7631-86-9 | Silica | 3 | ANTICAKING | | 231-545-4 | H - 51 |
| 100-51-6 | benzyl alcohol | 0.824 | PRESERVATIVE | | 202-859-9 | EUXYL 900 |
| 70445-33-9 | Ethylhexylglycerin | 0.175 | PRESERVATIVE | | 408-080-2 | EUXYL 900 |
| 10191-41-0 | Tocopherol | 0.001 | ANTIOXIDANT | | 233-466-0 | EUXYL 900 |

**APPENDIX II**

**AUTHENTIFICATION PAGE**

**QUALITY ASSURANCE**
**CERTIFICATE OF CONFORMITY**

**AUTHENTIFICATION PAGE**

I am aware that the study number DA25A635

has been conducted according to the STUDY PROTOCOL

| | | | | | |
|---|---|---|---|---|---|
| Dr. Sujittra SOMBUNTHAM<br>Dermatologist | Date | January 26, 2026 | Signature |  | Digitally signed by Sujittra SOMBUNTHAM<br>DN: cn=Sujittra SOMBUNTHAM, o, ou, email=technical@dermscanasia.com, c=TH<br>Date: 2026.01.26 13:35:18 +07'00' |
| Laddawan HENGSAMAE<br>Technician | Date | January 26, 2026 | Signature |  | Digitally signed by Laddawan HENGSAMAE<br>DN: cn=Laddawan HENGSAMAE, o, ou, email=lhe@dermscanasia.com, c=TH<br>Date: 2026.01.26 13:35:08 +07'00' |

Any modifications are the sole responsibility of the author of the modification, whether he/she is acting for the Sponsor or independently.

The on-line publishing, on the Internet, of this study protocol/report with the names and signatures is strictly prohibited.

**QUALITY ASSURANCE**
**CERTIFICATE OF CONFORMITY**

QUALITY ASSURANCE

The described study has been conducted in the spirit of the Good Clinical Practice defined by the ICH Topic E6 "Note for Guidance and good clinical practice" (CPMP/ICH/135/95), the Helsinki Declaration (1964, WMA) and its successive updates.

The study has been conducted according to Standard Operating Procedures and to the study protocol defined with the sponsor. All the case report form and data were checked.

Controls on data veracity and conformity with the protocol have been performed and confirmed by persons participating in the study (APPENDIX II).

**Certificate of conformity**

I am aware that the study DA25A635 has been conducted according to the "**Quality Assurance**" described before.

**There was no event which may have affected the quality or integrity of the data**.

| | | | | | |
|---|---|---|---|---|---|
| Atippaporn BOONVANICH<br>Quality Assurance Manager | Date | January 26, 2026 | Signature | Atippaporn | Digitally signed by Atippaporn BOONVANICH<br>DN: cn=Atippaporn BOONVANICH, o, ou, email=aro@dermscanasia.com, c=TH<br>Date: 2026.01.26 13:34:36 +07'00' |